CLAIMS

1. The use of 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a cancer selected from breast, colon, rectal, and liver cancer; wherein the cancer has a stromal derived factor-1 (SDF-1) level of at least 10 fragments per kilobase of exon per million reason (FPKM); provided that the use is not in combination with an immune checkpoint inhibitor.

2. The use according to claim 1**,** wherein 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide is the sole pharmaceutically active agent.

3. The use according to any one of claims 1 to 2**,** wherein the cancer is a breast cancer.

4. The use of 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a bladder cancer; wherein the bladder cancer has a stromal derived factor-1 (SDF-1) level of at least 10 fragments per kilobase of exon per million reason (FPKM); provided that the use is not in combination with an immune checkpoint inhibitor.

5. The use according to any one of claims 1 to 2**,** wherein the cancer is a colon cancer.

6. The use according to any one of claims 1 to 2**,** wherein the cancer is a rectal cancer.

7. The use according to any one of claims 1 to 2**,** wherein the cancer is a liver cancer.

8. The use according to any preceding claim**,** wherein cancer cells are eliminated.

9. The use according to any preceding claim**,** wherein tumour mass is reduced.

10. The use according to any preceding claim, wherein the SDF-1 level is at least 11 FPKM.

11. The use according to any preceding claim, wherein the SDF-1 level is at least 12 FPKM.

12. The use according to any preceding claim, wherein the SDF-1 level is at least 13 FPKM.

13. The use according to any preceding claim, wherein the SDF-1 level is at least 14 FPKM.

14. The use according to any preceding claim, wherein the SDF-1 level is at least 15 FPKM.

15. The use according to any preceding claim, wherein the SDF-1 level is at least 16 FPKM.

16. The use according to claim 4, wherein 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide is the sole pharmaceutically active agent.